Analyst Sits On Fence While Initiating Calliditas Citing ‘Near-Term Opportunity But Longer-Term Questions’
Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ:CALT) with a Neutral rating and an $18 price target. The analyst is impressed with…